Pain

​A 2024 systematic review published in Pharmaceuticals analysed 40 clinical and preclinical studies and concluded that CBD demonstrates analgesic and anti-inflammatory properties, primarily through activation of TRPV-1 and 5HT-1A receptors and allosteric modulation of CB1 receptors. The review found CBD to be effective and safe for reducing pain, with particular therapeutic promise for osteoarthritis and chronic pain management.

A separate 2024 systematic review in Pain Management Nursing synthesised 15 studies and found pain reduction ranging from 42% to 66% with CBD alone and CBD with THC. The authors noted that most measurement was through self-reporting and scales, and called for more robust study designs.

A 2025 living systematic review conducted by Oregon Health & Science University for the Agency for Healthcare Research and Quality (the most comprehensive ongoing review of cannabinoids for chronic pain) found that while isolated CBD alone showed limited effects on pain in the four RCTs analysed, full spectrum and comparable THC:CBD ratio products showed more promising results. Notably, this review highlighted that cannabis products are complex and cannot be reduced to single-compound analysis. The researchers emphasised that the field urgently needs more studies on whole-plant and full spectrum formulations, which is exactly what LuxCBD uses.

1. García-Sanz, V., et al. (2024). “Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain.” Pharmaceuticals, 17(11), 1438. DOI: 10.3390/ph17111438

2. Mohammed, S.Y., et al. (2024). “Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review.” Pain Management Nursing, 25(2), e76-e86. DOI: 10.1016/j.pmn.2023.10.002

3. Chou, R., et al. (2025). “Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update.” Agency for Healthcare Research and Quality (AHRQ). Published in Annals of Internal Medicine.

Anxiety

A large case series published in The Permanente Journal tracked 103 adult psychiatric patients using CBD as an adjunct treatment for anxiety and sleep. Within the first month, anxiety scores decreased in 79.2% of patients and remained decreased throughout the study. CBD was well tolerated in all but three patients.

A 2025 open-label pilot clinical trial published in Biomedicines tested a hemp-derived, full spectrum, high-CBD product in patients with anxiety. The study found significant improvement in anxiety, mood, quality of life, sleep, and executive function after treatment with just 30mg CBD per day. This is particularly relevant because it used a full spectrum product at a dose comparable to LuxCBD’s 30mg cubes, providing evidence that lower doses of full spectrum products may be more effective than the high-dose isolates (300-800mg) used in earlier studies.

1. Shannon, S., et al. (2019). “Cannabidiol in Anxiety and Sleep: A Large Case Series.” The Permanente Journal, 23, 18-041. DOI: 10.7812/TPP/18-041

2. Gruber, S.A., et al. (2025). “Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study.” Biomedicines, 13(8), 1874. DOI: 10.3390/biom13081874

3. Hayley, A.C., et al. (2022). “Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance.” Neuroscience & Biobehavioral Reviews. DOI: 10.1016/j.neubiorev.2022.104922

SLEEP

A 2024 randomised controlled pilot trial published in the Journal of Clinical Sleep Medicine tested 150mg nightly CBD for primary insomnia. The CBD group showed superior objective sleep efficiency after two weeks and reported greater wellbeing throughout the trial, with only mild side effects and no impact on daytime cognition.

A 2025 double-blind randomised clinical trial tested a CBD-terpene formulation (300mg CBD with eight terpenes) in 125 people with insomnia using a crossover design. The study found improvements in restorative sleep stages, supporting the entourage effect theory that full spectrum formulations (CBD combined with terpenes and other plant compounds) may offer benefits beyond isolated CBD.

The emerging consensus across the research is that CBD doesn’t force sleep or force calm. It creates the conditions for your body to regulate itself. It reduces the noise, the tension, the overactivation, and lets your system do what it already knows how to do.

1. Narayan, A.J., et al. (2024). “Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing.” Journal of Clinical Sleep Medicine, 20(5), 753-763. DOI: 10.5664/jcsm.10998

2. Journal of Clinical Sleep Medicine (2025). “Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover trial.” DOI: 10.5664/jcsm.11324

Immune Function

A 2023 clinical study published in Nutrients tested eight weeks of daily 50mg oral CBD in healthy individuals and found improved sleep quality and enhanced natural killer cell cytotoxicity (a key marker of immune function). This suggests that consistent, moderate CBD supplementation may support not just mental health and sleep, but broader immune regulation.

1. Nutrients (2023). “Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity.” Nutrients, 15(19), 4173. DOI: 10.3390/nu15194173

Important: LuxCBD does not make medical claims. These studies are presented for transparency and education. CBD is a supplement, not a medication. We always encourage people to consult their healthcare provider